The selection comes a year ahead of the city’s municipal elections, where all 25 seats on the council will be up for grabs. The council currently has a 14-11 balance in favor of Democrats.
The Greenfield-based animal health unit is gearing up for independence after 65 years as part of drugmaker Eli Lilly and Co. But Elanco has been struggling, and top management will have to work hard to stabilize the operation.
Host Mason King talks with two local marketing experts — Bruce Bryant, president and creative director of Promotus Advertising, and Ken Ungar, president of Charge — about whether Lilly made the right move in taking its logo off a race car driven by Conor Daly, whose father used a racial slur 35 years ago.
We understand that companies face difficult decisions when it comes to protecting their brands. But IBJ posits that Lilly’s decision to punish a race car driver for something his father said before he was born is the kind of decision that can set back progress made on racial tolerance and equality.
A boom in major U.S. pharmaceutical stocks is creating a swarm of activity around an exchange-traded fund tracking major drugmakers like Eli Lilly and Co.
During the past 20 years, Riley Children’s Foundation has raised $500 million, the majority of which has been spent for pediatric research and patient programs at Riley Hospital.
Jason Vasquez co-founded DeveloperTown, and created and evolved its repeatable technology package and processes to build more than 200 projects using what is now a 20-plus-person software team.
The Greenfield-based animal health unit has posted more than a half-billion dollars in losses in the past three years, and it will face huge new corporate expenses as it goes its separate way after more than a half-century as part of Eli Lilly and Co.
The American Medical Association recently called on regulators to monitor competition among the three drugmakers who control the market—Indianapolis-based Eli Lilly and Co., Denmark-based Novo Nordisk and Paris-based Sanofi.
After decades of being starved of innovative treatments for serious conditions like cancer, diabetes and kidney disease, China’s 1.4 billion people are becoming a prime target for Eli Lilly and other pharmaceutical companies.
Elanco Animal Health Inc. could see a market value of as much as $20 billion, according to Bloomberg Intelligence. At that valuation, a share sale could raise as much as $5 billion.
The university said it has hired 33 research faculty to help under the “Grand Challenges” program in precision health, an initiative it rolled out two years ago.
The drug, launched in 2014, is one of Lilly’s fastest-growing medicines, but its fate could hinge on the results of another clinical trial for heart benefits. The Indianapolis-based drugmaker plans to release results later this year.
